Chimeric antigen receptor T-cell (CAR-T) therapies have become standard of care for certain haematological malignancies due to their unprecedented specificity to the patients’ individual immune system. Despite the theoretical advantages, CAR-T therapies have lagged behind ‘off-the-shelf’ cancer drugs due to the logistical difficulties of manufacturing and administration.
During the 2019 American Society of Hematology (ASH) conference on December 6–10 in Orlando, Florida, bi-specific T-cell engager (BiTE) antibodies were presented as a potential off-the-shelf alternative to CAR-T therapies, mainly due to their mechanism of action, which induces similar anti-cancer immune response as CAR-Ts without the constraints associated with manufacturing individualized cell-based therapies. A point of entry for this relatively new treatment approach is the multiple myeloma (MM) market, which currently lacks novel immuno-oncology (IO) options.
Go deeper with GlobalData
Bristol-Myers Squibb’s (BMS) acquisition strategy has led to a significant expansion of its IO portfolio, placing the company a step ahead of the competition, mainly due to its ongoing pivotal trials with Bluebird Bio’s CAR-T therapy bb2121 and Celgene’s BiTE CC-93269.
Gilead Sciences’ Yescarta and Novartis’ Kymriah are the only two CAR-T therapies on the IO market, but neither has approved use for the treatment of MM. This is because these target the B-cell receptor CD19, often overexpressed in haematological malignancies, though MM plasma cells have been shown to lose CD19 expression during malignant transformation.
Instead, the B-cell maturation antigen (BCMA), a B-cell transmembrane receptor, has been shown to remain present and up-regulated in malignant plasma cells, thus making it a more viable target. Therefore, it is highly anticipated that the BCMA-targeting CAR-T therapy bb2121 will be approved to become the first CAR-T to market in MM.
During the 2019 ASH conference, BMS presented the interim results of its Celgene-acquired drug CC-93269. The ongoing phase one trial (NCT03486067) has shown promising data that point towards the potential of BiTEs to rival CAR-T therapies. CC-93269 targets cytotoxic T-cells CD3+ receptor and BCMA simultaneously to potentiate T-cell action on malignant cells. CC-93269 achieved an impressive 89% overall response rate (ORR) and 44% complete response rate (CRR) in heavily pretreated patients with refractory MM. By contrast, bb2121 yielded a 73% ORR and 31% CRR in the pivotal KarMMa trial.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAlso competing for a first-to-market and first-in-class position for BiTEs in MM are Regeneron with REGN-5459 and Amgen with AMG-420. Though no data have yet been published from the phase one / two non-pivotal trials, AMG-420 had encouraging data from its Phase I trial. Although there are promising initial results for BiTEs, they are expected to reach the market in MM after CAR-T.
BMS is well-positioned to lead the IO MM market in the near future with its CAR-T therapy bb2121 and later on with the addition of its BiTE antibody CC-93269. While CAR-T therapy is a more established therapy for haematological malignancies, BiTEs show potential to become the future standard of therapy.
Therefore, while there are other companies developing BiTEs for MM, CC-93269 holds a key position in the haematology pipeline for BMS, whether the future steers the preferred treatment towards BiTEs or remains with CAR-T therapies.
Related Company Profiles
Chorokbaem Co Ltd
Bristol-Myers Squibb Co
BMS AS
American Society of Hematology
ORR Corporation